Gensight Biologics Reaches Deal With ANSM For Opening Of Lumevoq Early Access Program In France
Refinitiv1분 미만 읽기
Gensight Biologics SA SIGHT:
GENSIGHT BIOLOGICS REACHES AGREEMENT WITH ANSM FOR OPENING OF LUMEVOQ® NAMED EARLY ACCESS PROGRAM (AAC) IN FRANCE
GENSIGHT BIOLOGICS SA - TARGETS Q3 2025 FOR FINALIZING DOSE-RANGING STUDY PROTOCOL
GENSIGHT BIOLOGICS SA - AAC PROGRAM TARGETED TO OPEN IN Q4 2025
이 뉴스를 읽으려면 로그인하거나 평생 무료 계정을 만드십시오